HISTAMINE METABOLITES IN CEREBROSPINAL-FLUID OF PATIENTS WITH CHRONIC-SCHIZOPHRENIA - THEIR RELATIONSHIPS TO LEVELS OF OTHER AMINERGIC TRANSMITTERS AND RATINGS OF SYMPTOMS

被引:107
作者
PRELL, GD
GREEN, JP
KAUFMANN, CA
KHANDELWAL, JK
MORRISHOW, AM
KIRCH, DG
LINNOILA, M
WYATT, RJ
机构
[1] CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029
[2] ST ELIZABETH HOSP,NIMH,NEUROPSYCHIAT BRANCH,WASHINGTON,DC 20032
[3] NIAAA,DIV INTRAMURAL CLIN & BIOL RES,BETHESDA,MD 20205
关键词
HISTAMINE METABOLITE; CEREBROSPINAL FLUID; (SCHIZOPHRENIA);
D O I
10.1016/0920-9964(94)00034-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Levels of the histamine metabolites, tele-methylhistamine (t-MH) and tele-methylimidazoleacetic acid (t-MIAA), and metabolites of other aminergic transmitters and of norepinephrine were measured in cerebrospinal fluid of 36 inpatients with chronic schizophrenia and eight controls. The mean t-MH level from controls was nearly identical to the levels seen previously in healthy volunteers. Compared with controls, the mean level of t-MH in the schizophrenic patients was 12.6-fold (higher (p=0.006); 21 of the patients had levels exceeding the range of controls. There was no significant difference (p>0.05) in levels of other analytes, although the levels of t-MH correlated significantly with those of t-MIAA, homovanillic acid, 3,4-dihydroxyphenylacetic acid, norepinephrine, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindoleacetic acid. The difference in levels of t-MH were not attributable to medication, since those taking (n=10) or withdrawn from (n=26) neuroleptic drugs had nearly the same mean levels of t-MH; each group had higher levels than controls (ANOVA: p<0.05). Patients with or without tardive dyskinesia showed no significant differences in means of any analyte. Only levels of t-MH-among those with schizophrenia correlated with positive symptom scores on the Psychiatric Symptom Assessment Scale (r(s)=0.45, p<0.02). The elevated levels of t-MH in cerebrospinal fluid, which represent histamine that was released and metabolized, suggest increased central histaminergic activity in patients with chronic schizophrenia.
引用
收藏
页码:93 / 104
页数:12
相关论文
共 96 条
  • [1] INTERACTING NEUROTRANSMITTER SYSTEMS - A NONEXPERIMENTAL APPROACH TO THE 5HIAA-HVA CORRELATION IN HUMAN CSF
    AGREN, H
    MEFFORD, IN
    RUDORFER, MV
    LINNOILA, M
    POTTER, WZ
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1986, 20 (03) : 175 - 193
  • [2] American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd
  • [3] AUTIO V, 1949, ANN MED EXP BIOL FEN, V27, P87
  • [4] BALLENGER JC, 1983, NEUROBIOLOGY CEREBRO, V2, P143
  • [5] PHARMACOLOGY OF THE NOVEL H2 ANTAGONIST FAMOTIDINE - INVITRO STUDIES
    BERTACCINI, G
    CORUZZI, G
    POLI, E
    ADAMI, M
    [J]. AGENTS AND ACTIONS, 1986, 19 (3-4): : 180 - 187
  • [6] BIGELOW LB, 1989, PSYCHOPHARMACOL BULL, V25, P168
  • [7] DIFFERENT LOCALIZATION OF HISTIDINE DECARBOXYLASE AND HISTAMINE-N-METHYLTRANSFERASE IN RAT-BRAIN
    BISCHOFF, S
    KORF, J
    [J]. BRAIN RESEARCH, 1978, 141 (02) : 375 - 379
  • [8] BLANDINA P, 1989, J PHARMACOL EXP THER, V249, P45
  • [9] DESENSITIZATION OF HISTAMINE-H(1) RECEPTOR-MEDIATED INOSITOL PHOSPHATE ACCUMULATION IN GUINEA-PIG CEREBRAL-CORTEX SLICES
    BRISTOW, DR
    BANFORD, PC
    BAJUSZ, I
    VEDAT, A
    YOUNG, JM
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (01) : 269 - 274
  • [10] BROWN DD, 1959, J BIOL CHEM, V234, P2948